Crinetics Pharmaceuticals, Inc. Total Assets
Crinetics Pharmaceuticals, Inc. (CRNX) had Total Assets of $1.32 billion as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Assets
us-gaap:Assets · last filed 2026-08-03
- 2026-06-30: Assets $1.32B.
- 2026-03-31: Assets $1.40B.
- 2025-12-31: Assets $1.13B.
- 2025-09-30: Assets $1.20B.
| Period end | Assets |
|---|---|
| 2026-06-30 | $1.32B 10-Q · filed 2026-08-03 |
| 2026-03-31 | $1.40B 10-Q · filed 2026-05-07 |
| 2025-12-31 | $1.13B 10-Q · filed 2026-08-03 |
| 2025-09-30 | $1.20B 10-Q · filed 2025-11-06 |
| 2025-06-30 | $1.29B 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.36B 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.43B 10-K · filed 2026-02-26 |
| 2024-09-30 | $937.37M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $935.53M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $978.15M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $635.35M 10-K · filed 2025-02-27 |
| 2023-09-30 | $641.54M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $293.25M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $314.01M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $352.18M 10-K · filed 2024-02-28 |
| 2022-09-30 | $384.88M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $421.73M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $333.29M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $351.01M 10-K · filed 2023-02-28 |
| 2021-09-30 | $209.36M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $216.93M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $163.55M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $183.44M 10-K · filed 2022-03-30 |
| 2020-09-30 | $200.32M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $217.12M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $123.88M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $130.38M 10-K · filed 2021-03-30 |
| 2019-09-30 | $142.51M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $155.15M 10-Q · filed 2019-08-13 |
| 2019-03-31 | $166.76M 10-Q · filed 2019-05-13 |
| 2018-12-31 | $171.41M 10-K · filed 2020-03-09 |
| 2018-09-30 | $176.68M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $74.70M 10-Q · filed 2018-08-30 |
| 2017-12-31 | $15.60M 10-K · filed 2019-03-13 |